

1 **Rapid and efficient testing of the toxicity of graphene-related** 2 **materials in primary human lung cells**

3 *Javier Frontiñan-Rubio*^{1,2}, *Viviana Jehová González*², *Ester Vázquez*^{2,3*} and
4 *Mario Durán-Prado*^{1*}

5 1 Universidad de Castilla-La Mancha. Faculty of Medicine, 13071, Ciudad Real, Spain

6 2 Universidad de Castilla-La Mancha. Instituto Regional de Investigación Científica
7 Aplicada (IRICA), 13071, Ciudad Real, Spain

8 3 Universidad de Castilla-La Mancha. Faculty of Chemical Science and Technology,
9 13071, Ciudad Real, Spain

10 **Abstract**

11 Background

12 Graphene and its derivative materials are manufactured by numerous companies and
13 research laboratories, during which processes they can come into contact with their
14 handlers' physiological barriers—for instance, their respiratory system. Despite their
15 potential toxicity, these materials have even been used in face masks to prevent COVID-
16 19 transmission. The increasingly widespread use of these materials requires the design
17 and implementation of appropriate, versatile, and accurate toxicological screening
18 methods to guarantee their safety. Murine models are adequate, though limited when
19 exploring different doses and lengths of exposure—as this increases the number of
20 animals required, contrary to the Three R's principle in animal experimentation. This
21 article proposes an *in vitro* model using primary, non-transformed normal human
22 bronchial epithelial (NHBE) cells as an alternative to the most widely used model to date,
23 the human lung tumor cell line A549. The model has been tested with three graphene
24 derivatives—graphene oxide (GO), few-layer graphene (FLG), and small FLG (sFLG).

25 Results

26 We observed a cytotoxic effect (necrosis and apoptosis) at early (6- and 24-hour)
27 exposures, which intensified after seven days of contact between cells and the
28 graphene-related materials (GRMs)—with cell death reaching 90% after a 5 µg/mL dose.
29 A549 cells are more resistant to necrosis and apoptosis, yielding values less than half of
30 NHBE cells at low concentrations of GRMs (between 0.05 and 5 µg/mL). Indeed, GRM-
31 induced cell death in NHBE cells is comparable to that induced by toxic compounds such
32 as diesel exhaust particles on the same cell line.

33 Conclusions

34 We propose NHBE as a suitable model to test GRM-induced toxicity, allowing refinement
35 of the dose concentrations and exposure timings for better-designed in vivo mouse
36 assays.

37 *Keywords: Lung, primary cells, necrosis, apoptosis, graphene*

38 **Background**

39 Although it was initially assumed that the primary interaction of graphene and graphene-
40 related materials (GRMs) with humans was limited to their production and handling [1,
41 2], there is an increasing number of applications of these compounds in skin sensors,
42 clothes, and accessories. This makes it necessary to establish safe-by-design
43 production protocols and explore the interaction of this family of materials with different
44 human physiological barriers prior to their commercialization [3, 4, 5, 6, 7, 8]. One recent
45 example of their commercial application is graphene-coated face masks to prevent the
46 transmission of COVID-19—which were withdrawn in some countries because of their
47 possible toxic effect on the respiratory tract [9, 10, 11].

48 Extensive research has been carried out on this topic, particularly on the interaction of
49 graphene-related materials (GRMs) with the lung barrier. However, this has yielded
50 contradictory results. First, because there are multiple types of GRMs—with varying
51 sizes, oxidation degrees, or number of layers, among other aspects, which interact with
52 cells in different ways [3]. Second, an even more significant problem is the lack of
53 standardization in toxicological screening methods, making it difficult to compare the
54 effects of different GRMs. As a result, choosing the best material for commercial
55 applications such as healthcare products, e.g., face masks, is often tricky. A standard
56 model needs to be established for a method to become standardized. There are currently
57 141 articles available in PubMed which analyze the interaction of graphene and GRMs
58 with the lung (search keywords: graphene, lung, and toxic), 82 of which evaluated
59 graphene-induced toxicity in the lung in vivo or in vitro. Of these 82 articles, 24 used
60 mouse (nine of these examining graphene exposure through the respiratory tract) and
61 12 used rat (six of these examining graphene exposures through the respiratory tract) in
62 vivo models; one publication used 3D in vitro airway models [12]; and 45 of these
63 publications used cultured in vitro lung cells—with diverse concentrations of GRMs that
64 were added in acute (41 publications) or sub-acute (4 publications) doses.

65 The in vitro model—culturing lung cells in monolayers—is the most simple, reproducible,
66 and versatile model. The major advantage of this approach is that it makes it easy to
67 assay multiple concentrations and timings, from acute (high dose, short periods) to
68 chronic (low dose, long periods). However, the main problem is that the gold standard
69 for this model, the human tumor cell line A549, does not have the same physiology as
70 normal airway lung cells. Indeed, A549 cells are highly resistant to the effect of
71 compounds such as GO, even though it can be internalized [13, 14, 15, 16, 17, 18, 19].
72 In vivo models, either with mice or rats, are probably more appropriate. However, their

73 major limitation is that a large number of animals are necessary to explore different
74 concentrations and exposure times, which opposes the Three R's principle in animal
75 experimentation [20]. Indeed, to perform in vivo experiments, it is mandatory to obtain
76 first strong enough in vitro results to set up an animal protocol and obtain the Ethical
77 Committees' approval.

78 Moreover, making animals inhale the desired amount of GRMs poses an additional
79 problem. 3D in vitro airway models are a promising intermediate between in vitro and in
80 vivo models. To our knowledge, only one paper to date has implemented this approach,
81 using adenovirus-12 transformed cells (BEAS-2B) sprayed with an aerosol exposure
82 system. However, this method is expensive and time-consuming, as it only allows testing
83 one condition per experiment [12].

84 This article presents an easy, reproducible, and versatile in vitro 2D model and a battery
85 of contrasted cellular assays that could serve as the basis to establish a new standard
86 to compare all GRMs—those already known to date and new ones that could be
87 generated in the future. Primary human lung epithelial cells are more complex to culture
88 than cancer A549 or adenovirus transformed BEAS-2B cells. However, they are still
89 more manageable to set up than 3D models cultured with aerosol exposure systems.
90 Normal human bronchial epithelial (NHBE) cells are primary, non-immortalized lung
91 epithelial cells that behave as normal lung cells [21]. Previous research has used these
92 as a model for testing drug delivery and absorption barrier [22] and toxicity [23, 24, 25,
93 26, 27]. Our study examined the toxicity of several GRMs using different concentrations
94 and exposure lengths on both NHBE and A549 lung tumor cells. Specifically, we used
95 one commercial graphene oxide (GO), a few-layer graphene (FLG), and a small FLG
96 (sFLG) synthesized both in our labs [28, 29], all of which had different oxidation degrees
97 ($GO \gg sFLG \approx FLG$) and lateral sizes ($GO > FLG > sFLG$). Our results indicate that NHBE
98 cells were susceptible to all GRMs assayed, reaching an exacerbated mortality after
99 seven days of incubation which was also significant at short incubation times (6 hours).
100 GRM dose and exposure length were the same, NHBE cell mortality was consistently
101 higher, almost double, than A549 cells. These results highlight the need to use
102 appropriate models to assay GRM-induced toxicity and provide easy-to-manage tools
103 and protocols to conduct comparative studies among the growing number of emergent
104 GRMs—prior to their testing in more complex in vivo models.

105 **3. Results**

106 *3.1 Characterization of nanomaterials*

107 Figure 1A shows standard high-resolution transmission electron microscopy (HRTEM)
108 images for GO, FLG, and sFLG. The size distribution of the graphene flakes shows
109 completely different lateral sizes depending on the type of material (Figures 1B and 1C),
110 with an average length of $1.18 \mu\text{m} \pm 994 \text{ nm}$ for GO, $300 \pm 23 \text{ nm}$ for FLG, and $36.04 \pm$
111 15 nm for sFLG. Thermogravimetric analysis (TGA) (Figure 1D) of GO, FLG, and sFLG
112 was performed under a nitrogen atmosphere. The weight loss at a temperature of
113 600°C —corresponding to the oxygen-containing groups on the graphene layers—was
114 57.30%, 4.81%, and 33.30% for GO, FLG, and sFLG, respectively. The significant mass
115 loss of GO and sFLG between $100\text{--}300^\circ\text{C}$ was expected to decompose functional
116 groups ($-\text{OH}$, $-\text{COOH}$, and $-\text{C}-\text{O}-\text{C}$) [30, 31] that are not found on FLG. Raman
117 spectroscopy is illustrated in Figure 1E, indicating the presence of the D band (1350 cm^{-1} ,
118 related to some defects in the carbon rings), G band (1580 cm^{-1} , associated to sp^2
119 carbon bonds in the hexagonal structure), and 2D band (2700 cm^{-1} , related to the
120 number of graphene layers and the quality of carbon rings) [32]. For carbon
121 nanomaterials, two main parameters need to be considered in Raman spectra: the
122 intensity ratio between the D and G bands (I_D/I_G), to quantify the density of defects in
123 graphene [33]; and the shape of the 2D band, to determine the number of layers (N_G)
124 [34]. The I_D/I_G values obtained for the nanomaterials were 0.94, 0.42, and 1.34 for GO,
125 FLG, and sFLG, respectively. GO and sFLG showed the highest I_D/I_G values due to these
126 having a more significant amount of defects than FLG, which is consistent with the TGA
127 results. The increased D band in sFLG is related to the small size of graphene layers
128 compared to the number of functional groups at the edges. At the same time, GO shows
129 a low intensity in the 2D band related to higher structural defects of its carbon rings [35].
130 In the case of FLG and sFLG, it was possible to calculate the average number of layers—
131 three in each case [34]. Elemental analysis of GO, FLG, and sFLG (Figure 1F) yielded a
132 percentage of 48.37% oxygen in the GO sample, 6.53% in FLG, and 9.19% in sFLG—
133 ...results which are consistent with those obtained with other characterization
134 techniques. The nanomaterial powders were re-dispersed in the different culture media
135 (DMEM with/without FBS and completed BEGM) at $5 \mu\text{g/ml}$ (Supplementary Figure 1A-
136 C) and the colloidal stability of the nanomaterials was studied through UV-Vis absorption
137 spectroscopy for 24 h, (see methods). Supplementary Table 1 shows the average
138 sedimentation at 2h and 24 h for all the different nanomaterials. sFLG is the nanomaterial
139 with the lowest sedimentation in all the different culture media after 24h, which can give
140 an idea about the delivered dose in each treatment. It is also important to note that
141 although the sedimentation of GO after 2h depends on the culture media, after 24 h there
142 are no significant differences in the sedimentation of this nanomaterial in DMEM with
143 FBS or in completed BEGM. Same results are observed for FLG and sFLG. These data

144 can be explained due to the fact that BEGM incorporates complements that are similar
145 to those found in FBS, such as different proteins or BPE (bovine pituitary extract).

146 *3.2 Graphene induces necrosis in primary human bronchial epithelial cells*

147 GRMs can induce cell death by necrosis and apoptosis [36, 37]. Necrosis is an
148 uncontrolled mode of cell death involving loss of membrane integrity, which leads to
149 activation of inflammation in vivo [38]. Previous works have shown that GRM-induced
150 toxicity involves necrosis in different cell types and organs [28, 37], including lung tumor
151 cells [39]. However, the toxicity of GRMs remains undetermined in normal, primary
152 epithelial cells.

153 In NHBE cells, low doses of the different GRMs did not increase necrosis after 6 hours
154 of exposure (Figure 2A). A concentration of 5 µg/mL of GO—more oxidized—significantly
155 increased necrosis (10.6%) compared to control ($p < 0.05$). Higher doses of GO, FLG,
156 and sFLG (50 and 100 µg/mL) showed a significant and remarkable increase in necrosis,
157 reaching more than 30% for 50 µg/mL GO ($p < 0.01$) (Figure 2A). In cells exposed for 24
158 hours, 5 µg/mL GO and FLG significantly increased necrosis to 17.3% ($p < 0.001$) and
159 18.7% ($p < 0.01$) (Figure 2B). Higher doses of the different GRMs increased necrosis in a
160 generalized way, reaching 38% for 50 µg/mL FLG (Figure 2B).

161 When exposure to the different GRMs was extended up to seven days, necrosis
162 drastically increased for all compounds. Compared to their respective controls, a 5 µg/mL
163 dose of GO, FLG, and sFLG increased necrosis significantly. In particular, 5 µg/mL sFLG
164 induced 27.5% of necrosis (Figure 2C). Exposure to 100 µg/mL GO was the most
165 harmful, damaging more than 50% of cells (Figure 2C).

166 *3.3 Graphene induces apoptosis in primary human lung cells*

167 Apoptosis is a type of programmed cell death essential for maintaining cell homeostasis.
168 It is characterized by specific morphological nuclear changes such as condensation and
169 fragmentation and the appearance of apoptotic bodies [36, 40]. Apoptosis, as necrosis,
170 is one of the main mechanisms of GRM-induced cell death [36]. Our results indicate a
171 similar trend to that observed for necrosis, although percentages of apoptotic cells were
172 consistently lower than necrotic ones (Supplementary Figure 2).

173 In cells exposed for 6 hours, a significant increase in apoptosis induced by 0.5 µg/mL
174 FLG and sFLG was noted, reaching 7.7% and 6.8%, respectively (Supplementary Figure
175 1). Although the effect did not seem to be dose-dependent, percentages increased to
176 10–12% for higher GRM concentrations (5–100 µg/mL). The same trend was observed
177 at 24hour (Supplementary Figure 2B) and seven-day exposures (Supplementary Figure

178 2C)—the latter with apoptosis percentages above 20% at high concentrations (50–100
179 µg/mL). These results indicate that GRM-induced toxicity causes NHBE cells to die
180 preferentially by physical damage rather than programmed cell death.

181 *3.4 Cytotoxic effect of graphene in A549 lung tumor cells*

182 A549 is the lung cell line most widely used to assess the toxicity of nanomaterials,
183 including graphene [16, 41, 42]. First, we compared the morphological features between
184 A549 and NHBE cells without observing differences in cell size and morphology
185 (Supplementary Figure 3A, B), indicating two phenotypically similar cell types. Then, we
186 evaluated the toxicity of increasing doses of GO, FLG, and sFLG in A549 cells exposed
187 for 24 hours, comparing the results with those observed on NHBE cells (Figure 3). GRMs
188 induced a dose-dependent increase in necrosis, although the values were less than half
189 those of NHBE cells (shaded bars) at doses between 0.05 and 5 µg/mL. This difference
190 was reduced at higher concentrations (50–100 µg/mL) (Figure 3A). A similar trend was
191 observed in apoptosis, which was significant only for 50–100 µg/mL (Figure 3B). A549
192 cells grow in a different culture medium than NHBE cells, which includes 10% fetal
193 bovine serum (FBS). Previous research has shown that the presence of FBS in the
194 medium can reduce graphene-induced cytotoxicity [43]. Therefore, to evaluate the
195 possible effect of FBS, apoptosis and necrosis were assessed in A549 cells grown in the
196 FBS-free medium for 6 and 24h and exposed to 5 µg/mL GO, FLG, and sFLG for 24h
197 (Supplementary Figure 4). No differences in the levels of necrosis (Supplementary
198 Figure 4A) and apoptosis (Supplementary Figure 4B) were observed, suggesting that
199 the presence of FBS was not critical for the cytotoxic effect of the different GRMs in A549
200 cells. Therefore, A549 cells appear to be more resistant than NHBE to the cytotoxic
201 effects of GRMs and are insensitive at low concentrations—which would be a
202 physiological dose in terms of possible inhalation.

203 *3.5 Graphene drastically reduces the viability of primary human lung cells*

204 Prolonged exposure of NHBE cells to harmful compounds results in cell death and,
205 consequently, the detachment of cells from the culture plate surface [44]. Our study used
206 fluorescence microscopy to analyze the number of cells attached to the culture dish and
207 the viability of the remaining cells. Short time exposure (6 hours) of NHBE cells to GRMs
208 alters the number of attached cells and their viability without reaching significance
209 (Supplementary Figure 5). Similarly, there is a dose-dependent trend to the number of
210 cells per field decreasing in 24-hour treatments, reaching significance at high
211 concentrations—50 µg/mL sFLG and 100 µg/mL FLG generated reductions of 35.5%
212 and 43.7%, respectively (Figure 4A). There is no effect on A549 cells with GRM

213 concentrations of 0.05–5 $\mu\text{g}/\text{mL}$ (Figure 4A). A reduction was detected for GO at 50
214 $\mu\text{g}/\text{mL}$ and for all GRMs at 100 $\mu\text{g}/\text{mL}$, although always lesser than those values
215 observed for NHBE cells (Figure 4A). No differences were observed in the number of
216 A549 cells cultured in medium with FBS and medium without FBS and exposed to 5
217 $\mu\text{g}/\text{mL}$ of the different GRMs (Supplementary Figure 4C). A seven-day exposure to
218 GRMs profoundly impacted NHBE cell viability, significant for low doses of 0.5 $\mu\text{g}/\text{mL}$
219 GO and sFLG. For doses of 5 $\mu\text{g}/\text{mL}$ GO, FLG, and sFLG, there was a decrease of
220 86.2%, 81.1%, and 81.7%, respectively, which was even more significant for higher
221 doses (50–100 $\mu\text{g}/\text{mL}$ of GRMs reduced cell viability up to 90%) (Figure 4B).
222 Interestingly, for a seven-day exposure the effect on A549 cells was only observed at a
223 concentration of 100 $\mu\text{g}/\text{mL}$ (Figure 4B).

224 *3.6 Graphene alters cytosolic and mitochondrial Ca^{2+} and reactive oxygen species in* 225 *NHBE cells*

226 The next step was to examine the underlying mechanisms through which GRMs can
227 induce cell death. Based on the results detailed above, experiments were performed in
228 NHBE and A549 cells incubated for 24 hours with a 5 $\mu\text{g}/\text{mL}$ dose of GO, FLG, and
229 sFLG. Cell morphology was determined as a standard measure of cell wellness status
230 [45]. No morphological alterations in the width/length ratio were found (Supplementary
231 Figure 6A), although cell size decreased slightly in response to sFLG (Supplementary
232 Figure 6B). Calcium homeostasis and oxidative stress were then examined, as these are
233 key processes related to graphene toxicity [3, 28]. The free cytosolic Ca^{2+} level increased
234 by 20% in NHBE cells treated with all GRMs but showed no change in lung tumor A549
235 cells (Figure 5A). At the same time, there was a similar increase in mitochondrial Ca^{2+}
236 for NHBE cells treated with FLG and sFLG—an effect not found in A549 cells (Figure
237 5B).

238 One of the main mechanisms through which graphene generates toxicity is by increasing
239 oxidative stress [46]. For that reason, hydrogen peroxide (H_2O_2) and superoxide anion
240 (O_2^-) levels were analyzed. H_2O_2 and O_2^- were determined by fluorescence microscopy
241 in living cells with the H2DCFDA and MitoSOX probes. Levels of H_2O_2 increased by
242 51.3%, 46.3%, and 32.2% in NHBE cells treated with GO, FLG, and sFLG, respectively
243 (Figure 5C). No effect was observed in A549 lung tumor cells (Figure 5C). On the other
244 hand, O_2^- levels were not altered by exposure to GRMs, neither on NHBE nor on A549
245 cells (Figure 5D). Again, these results suggest that primary lung cells are more sensitive
246 than the tumor cell line.

247 *3.7 Comparison of GRM-induced toxicity in NHBE cells with the effect of other toxic*
248 *compounds*

249 NHBE cells have been used as a model in several in vitro lung toxicity studies [47, 48,
250 49]. Once it had been demonstrated that these cells were susceptible to GRM-induced
251 cytotoxicity, our results were compared with existing data on the effect of other toxic
252 compounds—i.e., cigarette smoke extract and diesel exhaust particles [25] [26]. After
253 performing a database search, data on NHBE cell necrosis and apoptosis were
254 compared to that extracted from research studies that used similar methodologies in
255 terms of mode of exposure and incubation times. This comparison allowed us to
256 establish that a 5 µg/mL dose of GO, FLG, and sFLG is as toxic as low concentrations
257 of cigarette smoke extract [25] or diesel exhaust particles [26], whereas 50 µg/mL doses,
258 especially in the case of FLG, damage cells in a similar magnitude to the highest doses
259 of the compounds found in the literature [23, 25, 26]. Their toxicity was only exceeded
260 by exposure to cigarette mainstream smoke [23] (Figure 6).

261 **4. Discussion**

262 In recent years, many potential graphene applications have emerged across different
263 research and innovation fields [3, 7, 8, 50, 51]. The growing interest in this material has
264 led to an increase in its production—and, consequently, in human exposure to it. Many
265 of these applications—e.g., face masks, sensors, and smart clothes—involve daily use
266 and thus continuous exposure [52, 53, 54]. In order to create safe-by-design protocols,
267 it is essential to study how graphene and GRMs interact with different human biological
268 barriers, especially those that will come into direct contact with them [2, 3]. Therefore,
269 assessing how graphene interacts with the respiratory system, especially the interaction
270 with the first chain of defense, the respiratory epithelium. These studies are crucial, for
271 example, for setting occupational exposure limits. On the other hand, it is necessary to
272 establish standardized criteria for this kind of studies [1, 3]. The scientific community
273 must conduct multiple studies, evaluating the potential impact of different GRMs at
274 different doses and exposure times. In addition, it is necessary to define the most
275 appropriate biological model to conduct these studies [3]. Finally, for an adequate toxicity
276 assessment, different GRMs should be well-characterized through standardized
277 protocols [55].

278 The major potential routes of graphene into the body are inhalation, ingestion, and
279 dermal adsorption [3]. Exposure to graphene is variable during its production process,
280 involving direct interaction with the respiratory tract if adequate personal protective
281 equipment is not used [56]. Concerns about the toxic effect of graphene on the lungs

282 also extend to its integration into everyday products such as face masks [52] and
283 biomedical applications such as intranasal immunization [57]. Moreover, different studies
284 on the biodistribution of graphene have demonstrated the presence of graphene in the
285 lung after intravenous [58, 59], oral [60], and intraperitoneal administration [61, 62]. This
286 suggests that the lung could also be damaged when other administration routes are
287 used.

288 Different studies have evaluated the pulmonary toxicity of graphene in murine models in
289 recent years, with contradictory results [3, 63, 64, 65, 66, 67, 68]. This is because the
290 impact of graphene depends on its different physicochemical characteristics,
291 concentration, and exposure time [3]. Bussy et al. recently observed GO inhalation could
292 induce lung granulomas that persist up to 90 days after exposition [69]. This suggests
293 that in vivo studies must evaluate its long-term effects. However, this is not very common.
294 On the other hand, the in vivo studies published to date, evaluating different conditions
295 and scenarios, required very large numbers of mice. To ensure the 3Rs principle and
296 reduce costs and time, it is essential to refine the in vivo exposure conditions prior to
297 conducting the experiments by using standardized in vitro toxicity assessment protocols.
298 However, the choice of cellular models for in vitro study is a crucial issue that should not
299 be taken lightly [70, 71].

300 In this work, we propose a model using primary normal human bronchial epithelial
301 (NHBE) cells, which have been used previously to study particle-generated lung toxicity
302 [23, 25, 26, 72]. The gold standard to study graphene-induced lung toxicity is the lung
303 tumor cell line A549 [73, 74]. Tumor cell models are cost-efficient, easy to use and
304 provide an unlimited material supply. However, they do not have the same characteristics
305 as normal cells, particularly regarding the composition and net charge of the plasma
306 membrane or the oxidative stress response—all of which are critical for interacting with
307 GRMs [3]. Indeed, some studies using A549 cells showed no toxicity after exposure to
308 high doses ($\geq 50 \mu\text{g/mL}$) of graphene, indicating that this cell line is highly resistant to
309 graphene-induced toxicity [75, 76, 77].

310 Therefore, the use of the NHBE model offers a more realistic scenario for toxicity
311 assessment. In this work, we have proposed a series of simple and reproducible toxicity
312 determination procedures for identifying variations in cell viability, from slight to acute
313 effects. The results indicate that low doses of different GRMs significantly increased
314 NHBE cell death, an effect not observed in A549 cells (Figures 2–4). Both cell lines, with
315 similar morphological characteristics (Supplementary Figure 3), showed different
316 behaviour in response to GRMs. This effect could be enhanced by differences in the

317 composition of the culture media of both models, especially by the presence of FBS in
318 the culture medium of A549 cells, which may be associated with a higher protein corona
319 in the graphene, therefore lower cytotoxicity [43]. Although the medium of NHBE cells
320 lacks FBS, it incorporates high concentrations of different protein complements,
321 producing the protein corona. However, to avoid this possible effect, the toxicity of the
322 different GRMs (5 µg/mL) was studied in A549 cells grown in FBS starvation without
323 observing significant differences. On the other hand, the results obtained in A549 cells
324 were similar to those reported in previous works [46, 65]. Differences were only due to
325 the intrinsic characteristics of tumoral cells A549—i.e., membrane dynamics and
326 resistance to oxidative stress [78].

327 However, to avoid underestimating the real impact of GRM-based toxicity on lung cells
328 and the cell model used, it is also crucial to combine different approaches. Studies
329 published to date quantifying cytotoxicity by classical methods may underestimate the
330 real in vitro cytotoxic impact of GRMs. Our study observed necrosis and apoptosis in
331 cells exposed for seven days (Figure 2C; Supplementary Figure 2C) to 5, 50, and 100
332 µg/mL doses were much higher, since it was related to a very small proportion of
333 surviving cells (Figure 4). The substantial increase in cell death at seven-day exposures
334 led us to focus our attention on a 24-hour exposure time—which is also the standard
335 exposure time in toxicity studies. Moreover, our study further evaluated other indirect
336 parameters of cell damage, such as alteration in Ca²⁺ homeostasis and ROS levels. We
337 observed that low doses of GRMs altered these parameters only in NHBE cells (Figure
338 5).

339 Our study assessed the toxicity of three well-characterized GRMs with different lateral
340 sizes and oxidation degrees. Regarding necrosis, 5 and 50 µg/mL GO (more oxidized)
341 generated an immediate and acute increase in this parameter compared to FLG and
342 sFLG, which was maintained over time (Supplementary Figure 7). On the other hand,
343 the size of the graphene was determinant in cytotoxicity at long times and low doses, as
344 suggested by the high toxicity effect of seven-day sFLG exposure. This result could also
345 be due to the fact that sFLG showed the lowest sedimentation after 24h (Supplementary
346 Figure 1), which could imply a higher interaction with the cells. This difference was not
347 observed at higher doses since the level of cytotoxicity generated was extremely high.
348 This trend was not observed regarding apoptosis, highlighting the importance of
349 combining different approaches to assess toxicity in the same study.

350 It has been fully demonstrated that small particles harm the lung [79], and graphene is
351 no exception. The toxicity of many of these particles has been studied previously using

352 the NHBE cell line. Therefore, to put our results into context, we compared graphene-
353 induced toxicity levels in NHBE cells with those of other toxic particles analyzed using
354 the same cell model. The toxicity levels induced by 5 µg/mL doses of GO, FLG, and
355 sFLG were comparable to those generated by low doses of toxic compounds such as
356 DEPs [26] and cigarette smoke extracts [25]. For 50 µg/mL doses (particularly FLG),
357 toxicity levels were similar to those induced by high doses of DEP compounds or
358 electronic cigarette smoke extracts [23, 25, 26]. For example, DEPs are generated by
359 diesel engines, one of the most important sources of anthropogenic particulate matter
360 emissions. These particles generate cytotoxicity in various cells, including NHBE [80, 81,
361 82]. Remarkably, different studies show that exposure to even low doses of these toxic
362 compounds has a detrimental effect on human health [23, 25, 26, 72]. The results
363 obtained in our study allow us to conclude that, for NHBE cells, a 5 µg/mL dose of GRMs
364 (considered as low) generated toxicity after 24 hours of exposure, and a dose of 50
365 µg/mL was as toxic as higher doses of other, well-studied toxic nanoparticles.

366 **Conclusions**

367 The management of graphene derivatives for their integration into everyday applications
368 such as face masks can involve regular direct contact between the nanomaterials and
369 the lung barrier. For this reason, it is essential to design accurate, fast, and easy-to-use
370 screening protocols to 1) assay the toxicity of current and potential novel GRMs prior to
371 their use in commercial applications, and 2) to increase the safety measures during their
372 preparation and handling at research laboratories and companies. For the first time, the
373 present work evaluates the harmful effect of different, well-characterized GRMs in a 2D
374 model of primary human bronchial epithelial cells. This model allowed us to ascertain
375 that the toxicity of several materials such as GO, FLG, and sFLG could be
376 underestimated when using the current standard model, the lung tumor cell line A549.
377 Indeed, our results indicated that lung cytotoxicity is proportional to the size and oxidation
378 degree of the compound, with GO being the most toxic one tested—as lethal as cigarette
379 compounds or DEPs even at low doses of 5 µg/mL. The use of primary, non-
380 immortalized, and non-tumorigenic cells can provide a more accurate assessment of the
381 interaction between GRMs and human lung cells—providing essential information for
382 further testing in animal models, thus allowing the fulfillment of the Three R's principle.

383 **Methods**

384 *GO synthesis*

385 GO was kindly provided by Grupo Antolin (Burgos, Spain). Before its use, the material
386 was washed to eliminate acid traces until the pH of the GO aqueous suspension was ~5

387 in several cycles of Milli-Q water addition, re-dispersion, and centrifugation (4000 rpm,
388 30 minutes). The final suspension was lyophilized at a temperature of -80°C and
389 pressure of 0.005 bar to obtain powdered GO.

390 *FLG and sFLG synthesis*

391 FLG and sFLG were prepared by ball milling treatment using melamine [83] and glucose
392 [84] as exfoliating agents, respectively, using a Retsch PM 100 planetary mill in both
393 cases.

394 Briefly, for FLG, graphite (7.5 mg SP-1 graphite powder, purchased from Bay Carbon,
395 Inc.) and melamine (22.5 mg, Sigma-Aldrich, ref. M2659) were mixed in a 25 mL
396 stainless steel jar with ten stainless steel balls (1-cm diameter) and treated at 100 rpm
397 for 30 minutes at room temperature and air atmosphere. After that, the resultant solid
398 was dispersed in 20 mL of water for further dialysis at 70°C , changing the washing water
399 periodically (five changes every 120 minutes, including one overnight). Finally, the
400 dispersion was left for five days to allow the sedimentation of graphite; the supernatant
401 was extracted and lyophilized at a temperature of -80°C and pressure of 0.005 bar.

402 For sFLG, graphite (75 mg SP-1 graphite powder, purchased from Bay Carbon, Inc.) and
403 D-glucose (4.5g, purchased from Panreac) were mixed in a 250 mL stainless steel jar
404 with 15 stainless steel balls (2-cm diameter). The jar was introduced in the planetary ball-
405 milling machine at room temperature and air atmosphere for 4 h. The obtained solid was
406 dispersed in 100 mL of water for further centrifugation (1500 rpm for 15 minutes) to
407 remove non-exfoliated graphite and partial glucose. The supernatant was dialyzed at
408 70°C to remove the glucose, changing the washing water periodically (seven changes
409 every 90 minutes, including one overnight). The resulting dispersion was left to rest for
410 five days at room temperature and air atmosphere. Then, the supernatant was
411 lyophilized at a temperature of -80°C and a pressure of 0.005 bar. The colloidal stability
412 in different culture media was studied using a UV-vis-NIR spectrophotometer (UV-Vis
413 Cary 5000) with 1 cm quartz cuvettes [85]. The concentration of the nanomaterials was
414 determined from the optical absorption at 386 nm for GO and at 660 nm for FLG and
415 sFLG, during 24 h at different intervals, and using the calibration lines reported in
416 Supplementary Table 2-4.

417 *Primary NHBE cells culture*

418 Primary normal human bronchial epithelial (NHBE) cells were obtained from LONZA
419 Walkersville Inc. (NHBE CC-2540; Lonza) from a single anonymous female donor, who
420 was a non-smoker with no respiratory pathology. NHBE cells were seeded and grown

421 according to the manufacturer's instructions. Briefly, cells were passaged once into a
422 T25 flask in BEBM Bronchial Epithelial Cell Growth Basal Medium (CC-3171, Lonza)
423 with BEGM Bronchial Epithelial Cell Growth Medium SingleQuots Supplements and
424 Growth Factors, containing Bovine Pituitary Extract [BPE], Hydrocortisone, human
425 Epidermal Growth Factor [hEGF], Epinephrine, Transferrin, Insulin, Retinoic Acid,
426 Triiodothyronine, and Gentamicin/Amphotericin-B (CC-4175, Lonza). The growth media
427 was changed every 48-72 hours. When cells exceeded 45% confluence, the volume of
428 the medium was doubled. Once cells reach 75-85% confluence, cells were re-seeded at
429 100,000 cells/T25 flask. Cells were passaged every seven days or when 85% confluency
430 was reached. We used Clonetics ReagentPack (CC-5034, Lonza) for cell subculture with
431 HEPES Buffered Saline Solution, Trypsin/EDTA, and Trypsin Neutralizing Solution. Cells
432 were maintained at 37°C in a 5% CO₂ atmosphere. All experiments were performed
433 between passages 1–5.

434 *Lung tumor A549 cell culture*

435 Human lung cancer cell line A549 was purchased from ATCC (ATCC® CCL-185). A549
436 cells were seeded and grown according to the manufacturer's instructions. Briefly, cells
437 were maintained in Dulbecco's modified Eagle's medium (DMEM) (#D6546; Sigma-
438 Aldrich) with 10% fetal bovine serum (FBS) (#F4135; Sigma-Aldrich), 1% L-glutamine
439 (#G7513; Sigma-Aldrich), and 1% Antibiotic Antimycotic Solution (#A5955-100ML
440 Sigma-Aldrich) at 37°C in a 5% CO₂ atmosphere. Cell medium was renewed 2-3 times
441 per week. The subcultivation ratio used was 1:8.

442 *Exposure of lung cells to GRMs*

443 GO, FLG, or sFLG (0.05, 0.5, 5, 50, and 100 µL) were added to NHBE and A549 cells
444 cultured in monolayers for up to 6 hours, 24 hours, and 7 days, depending on the assay.
445 For seven-day incubation, cells received fresh medium at 72 hours after GRM treatment.

446 *Determination of apoptosis and necrosis*

447 Viability and necrosis were performed as reported in earlier studies [28, 86, 87]. Briefly,
448 NHBE or A549 were seeded in 96-well cell culture plates and incubated for up to 6 hours
449 (10,000 cells/well), 24 hours (10,000 cells/well), and 7 days (2,500 cells/well) with GO,
450 FLG, or sFLG at increasing concentrations (0.05, 0.5, 5, 50, and 100 µg/mL). For FBS
451 starvation tests, A549 cells were pre-cultured for 6h or 24h in a serum-free medium. Cells
452 were then incubated with 10 µg/mL ethidium bromide (EtBr) (#46067; Sigma-Aldrich)
453 and 1 µM Calcein-AM (#C34852; Thermo Fisher). Viable cells, stained with green
454 Calcein-AM, and necrotic cells, stained with red EtBr, were determined by fluorescence

455 microscopy using a Cytation 5 Cell Imaging Multi-Mode Reader (20x objective; BioTek)
456 and analyzed with ImageJ 1.53. After image acquisition in living cells, samples were fixed
457 and permeabilized in cold methanol for 4 minutes and then stained with 1 µg/mL Hoescht
458 (#861405; Sigma-Aldrich) to visualize DNA. Apoptosis was quantified by qualitative
459 methods, as reported in earlier studies [28]. Results are presented as the number of cells
460 per field or as a percentage of necrotic or apoptotic cells vs. total (n=3).

461 *Morphological analysis*

462 For morphological analysis A549 and NHBE cells were seeded in a 6-well plate (50.000
463 cells/well), after 24 hours phase contrast images were acquired using an inverted
464 microscope. Cell area, width and length were analysed using ImageJ (N > 50 cells).

465 *Determination of Ca²⁺ and mitochondrial Ca²⁺ in single cells*

466 The intracellular Ca²⁺ levels were quantified using the probe Fluo-4 (#F23917; Thermo
467 Fisher). Cells were seeded in 96-well plates (10.000 cells/well) and incubated for 24
468 hours with 5 µg/mL of GO, FLG, or sFLG. Cells were then washed with PBS (5 minutes
469 twice) and loaded for 30 minutes with 1 µM Fluo-4. After a brief washout, cells were
470 imaged using a fluorescence microscope Nikon TiU (20x objective) and analyzed using
471 ImageJ 1.53. The results show the relative fluorescence units (RFUs) normalized vs.
472 control levels (n=3).

473 Levels of mitochondrial Ca²⁺ were quantified as described in earlier studies [86]. Briefly,
474 cells were seeded in 96-well plates (10.000 cells/well) and incubated for 24 hours with 5
475 µg/mL of GO, FLG, or sFLG. Cells were then loaded with 1 µM Calcein-AM (#C1430;
476 Thermo Fisher). Cytosolic Ca²⁺ fluorescence (Calcein AM) was quenched with 1 mM
477 CoCl₂. After washing in fresh medium, images were acquired using a Cytation 5 Reader
478 (Biotek) (20x objective) and analyzed using ImageJ 1.53 (n=3).

479 *Determination of O₂⁻ and H₂O₂ in single cells*

480 The level of intracellular reactive oxygen species was quantified in living cells using
481 MitoSox (#M36008; Thermo Fisher) for O₂⁻ and H₂DCFDA (#C6827; Thermo Fisher) for
482 H₂O₂. Cells were seeded in 96-well plates (10.000 cells/well) and incubated for 24 hours
483 with 5 µg/mL of GO, FLG, or sFLG. Cells were then washed with PBS (5 minutes twice)
484 and loaded 30 minutes with 1 µM MitoSOX and 2.5 µM H₂DCFDA. After 30 minutes, the
485 excess dye was washed off with PBS (5 minutes once). For H₂O₂ quantification, cells
486 were incubated at 37°C DMEM in darkness for 30 minutes. Images were acquired using
487 a Cytation 5 Reader (Biotek) (20x objective) and analyzed using ImageJ 1.53. The
488 results show relative fluorescence units (RFUs) normalized vs. control levels (n=3).

489 *Statistics*

490 Statistical analysis was performed with GraphPad Prism 8 (San Diego, CA, USA). To
491 determine the statistical significance between control cells and GRM-treated cells we
492 used Student t-test or one-way ANOVA (*p<0.05; **p<0.01, ***p<0.001; ****p<0.0001),
493 followed by a Bonferroni's post-hoc test. All graphs were designed with GraphPad Prism
494 8 (San Diego, CA, USA). Data are presented as mean \pm standard error of the mean
495 (SEM) of three independent experiments.

496 **Availability of data and materials**

497 The data sets used and/or analyzed during the current study are available from the
498 corresponding author on request.

499 **Competing interests**

500 The authors declare that they have no competing interests.

501 **Funding**

502 Financial support from the 785219-Graphene Core 2 and 881603-Graphene Core 3
503 European Union (Flagship project) and the Spanish Ministerio de Economía y
504 Competitividad (project CTQ2017-88158-R) is gratefully acknowledged.

505 **Author Contributions**

506 All authors discussed the results and contributed to the final manuscript. JFR carried out
507 the experiments and wrote the manuscript. VJG prepared and characterized the GRMs.
508 MDP and EV obtained resources, designed, and supervised the experiments, and wrote
509 the manuscript.

510 Bibliography

- 511 1. Pelin M, Sosa S, Prato M, Tubaro A. Occupational exposure to graphene based
512 nanomaterials: risk assessment. *Nanoscale*. 2018;10 34:15894-903; doi:
513 10.1039/c8nr04950e.
- 514 2. Xiaoli F, Qiyue C, Weihong G, Yaqing Z, Chen H, Junrong W, et al. Toxicology data of
515 graphene-family nanomaterials: an update. *Archives of toxicology*. 2020;94 6:1915-39;
516 doi: 10.1007/s00204-020-02717-2. <https://www.ncbi.nlm.nih.gov/pubmed/32240330>.
- 517 3. Fadeel B, Bussy C, Merino S, Vázquez E, Flahaut E, Mouchet F, et al. Safety Assessment
518 of Graphene-Based Materials: Focus on Human Health and the Environment. *ACS nano*.
519 2018;12 11:10582-620; doi: 10.1021/acs.nano.8b04758.
- 520 4. Hu X, Tian M, Xu T, Sun X, Sun B, Sun C, et al. Multiscale Disordered Porous Fibers for
521 Self-Sensing and Self-Cooling Integrated Smart Sportswear. *ACS nano*. 2020;14 1:559-
522 67; doi: 10.1021/acs.nano.9b06899. <http://www.ncbi.nlm.nih.gov/pubmed/31855404>.
- 523 5. Ergoktas MS, Bakan G, Steiner P, Bartlam C, Malevich Y, Ozden-Yenigun E, et al.
524 Graphene-Enabled Adaptive Infrared Textiles. *Nano letters*. 2020;20 7:5346-52; doi:
525 10.1021/acs.nanolett.0c01694.
- 526 6. Ahmed A, Jalil MA, Hossain MM, Moniruzzaman M, Adak B, Islam MT, et al. A
527 PEDOT:PSS and graphene-clad smart textile-based wearable electronic Joule heater
528 with high thermal stability. *Journal of Materials Chemistry C*. 2020;8 45:16204-15; doi:
529 10.1039/d0tc03368e.
- 530 7. Kabiri Ameri S, Ho R, Jang H, Tao L, Wang Y, Wang L, et al. Graphene Electronic Tattoo
531 Sensors. *ACS nano*. 2017;11 8:7634-41; doi: 10.1021/acs.nano.7b02182.
- 532 8. Zhong H, Zhu Z, Lin J, Cheung CF, Lu VL, Yan F, et al. Reusable and Recyclable
533 Graphene Masks with Outstanding Superhydrophobic and Photothermal Performances.
534 *ACS nano*. 2020;14 5:6213-21; doi: 10.1021/acs.nano.0c02250.
- 535 9. Pullangott G, Kannan U, S G, Kiran DV, Maliyekkal SM. A comprehensive review on
536 antimicrobial face masks: an emerging weapon in fighting pandemics. *RSC Advances*.
537 2021;11 12:6544-76; doi: 10.1039/d0ra10009a.
- 538 10. White CM: Are graphene-coated face masks a COVID-19 miracle – or another health
539 risk? [https://theconversation.com/are-graphene-coated-face-masks-a-covid-19-miracle-](https://theconversation.com/are-graphene-coated-face-masks-a-covid-19-miracle-or-another-health-risk-159422)
540 [or-another-health-risk-159422](https://theconversation.com/are-graphene-coated-face-masks-a-covid-19-miracle-or-another-health-risk-159422) (2021). Accessed 05/13/2021.
- 541 11. Pal K, Kyzas GZ, Kralj S, Gomes de Souza F. Sunlight sterilized, recyclable and super
542 hydrophobic anti-COVID laser-induced graphene mask formulation for indelible usability.
543 *Journal of Molecular Structure*. 2021;1233; doi: 10.1016/j.molstruc.2021.130100.
- 544 12. Di Cristo L, Grimaldi B, Catelani T, Vázquez E, Pompa PP, Sabella S. Repeated exposure
545 to aerosolized graphene oxide mediates autophagy inhibition and inflammation in a three-
546 dimensional human airway model. *Materials Today Bio*. 2020;6; doi:
547 10.1016/j.mtbio.2020.100050.
- 548 13. Jin C, Wang F, Tang Y, Zhang X, Wang J, Yang Y. Distribution of graphene oxide and
549 TiO₂-graphene oxide composite in A549 cells. *Biological trace element research*.
550 2014;159 1-3:393-8; doi: 10.1007/s12011-014-0027-3.
551 <https://www.ncbi.nlm.nih.gov/pubmed/24869803>.
- 552 14. Liao Y, Wang W, Huang X, Sun Y, Tian S, Cai P. Reduced graphene oxide triggered
553 epithelial-mesenchymal transition in A549 cells. *Scientific reports*. 2018;8 1:15188; doi:
554 10.1038/s41598-018-33414-x. <https://www.ncbi.nlm.nih.gov/pubmed/30315228>.
- 555 15. Tian X, Yang Z, Duan G, Wu A, Gu Z, Zhang L, et al. Graphene Oxide Nanosheets Retard
556 Cellular Migration via Disruption of Actin Cytoskeleton. *Small*. 2017;13 3; doi:
557 10.1002/smll.201602133. <https://www.ncbi.nlm.nih.gov/pubmed/27762498>.
- 558 16. Chang Y, Yang ST, Liu JH, Dong E, Wang Y, Cao A, et al. In vitro toxicity evaluation of
559 graphene oxide on A549 cells. *Toxicology letters*. 2011;200 3:201-10; doi:
560 10.1016/j.toxlet.2010.11.016. <https://www.ncbi.nlm.nih.gov/pubmed/21130147>.
- 561 17. Xu Z, Zhu S, Wang M, Li Y, Shi P, Huang X. Delivery of paclitaxel using PEGylated
562 graphene oxide as a nanocarrier. *ACS applied materials & interfaces*. 2015;7 2:1355-63;
563 doi: 10.1021/am507798d. <https://www.ncbi.nlm.nih.gov/pubmed/25546399>.
- 564 18. Rosli NF, Fojtu M, Fisher AC, Pumera M. Graphene Oxide Nanoplatelets Potentiate
565 Anticancer Effect of Cisplatin in Human Lung Cancer Cells. *Langmuir*. 2019;35 8:3176-
566 82; doi: 10.1021/acs.langmuir.8b03086.
567 <https://www.ncbi.nlm.nih.gov/pubmed/30741550>.

- 568 19. Hu W, Peng C, Lv M, Li X, Zhang Y, Chen N, et al. Protein Corona-Mediated Mitigation
569 of Cytotoxicity of Graphene Oxide. *ACS nano*. 2011;5 5:3693-700; doi:
570 10.1021/nn200021j.
- 571 20. Sneddon LU, Halsey LG, Bury NR. Considering aspects of the 3Rs principles within
572 experimental animal biology. *Journal of Experimental Biology*. 2017;220 17:3007-16; doi:
573 10.1242/jeb.147058.
- 574 21. Sato M, Shay JW, Minna JD. Immortalized normal human lung epithelial cell models for
575 studying lung cancer biology. *Respir Investig*. 2020;58 5:344-54; doi:
576 10.1016/j.resinv.2020.04.005. <https://www.ncbi.nlm.nih.gov/pubmed/32586780>.
- 577 22. Min KA, Rosania GR, Shin MC. Human Airway Primary Epithelial Cells Show Distinct
578 Architectures on Membrane Supports Under Different Culture Conditions. *Cell Biochem*
579 *Biophys*. 2016;74 2:191-203; doi: 10.1007/s12013-016-0719-8.
580 <https://www.ncbi.nlm.nih.gov/pubmed/26818810>.
- 581 23. Scheffler S, Dieken H, Krischenowski O, Aufderheide M. Cytotoxic Evaluation of e-Liquid
582 Aerosol using Different Lung-Derived Cell Models. *International journal of environmental*
583 *research and public health*. 2015;12 10:12466-74; doi: 10.3390/ijerph121012466.
- 584 24. Liu X, Cheng X, Wang F, Feng L, Wang Y, Zheng Y, et al. Targeted delivery of SNX-2112
585 by polysaccharide-modified graphene oxide nanocomposites for treatment of lung
586 cancer. *Carbohydrate polymers*. 2018;185:85-95; doi: 10.1016/j.carbpol.2018.01.014.
587 <http://www.ncbi.nlm.nih.gov/pubmed/29421063>.
- 588 25. Ding S, Hou X, Yuan J, Tan X, Chen J, Yang N, et al. Wedelolactone protects human
589 bronchial epithelial cell injury against cigarette smoke extract-induced oxidant stress and
590 inflammation responses through Nrf2 pathway. *International immunopharmacology*.
591 2015;29 2:648-55; doi: 10.1016/j.intimp.2015.09.015.
- 592 26. Colasanti T, Fiorito S, Alessandri C, Serafino A, Andreola F, Barbati C, et al. Diesel
593 exhaust particles induce autophagy and citrullination in Normal Human Bronchial
594 Epithelial cells. *Cell death & disease*. 2018;9 11:1073; doi: 10.1038/s41419-018-1111-y.
595 <http://www.ncbi.nlm.nih.gov/pubmed/30341285>.
- 596 27. Du J, Chi Y, Song Z, Di Q, Mai Z, Shi J, et al. Crocin reduces *Aspergillus fumigatus*-
597 induced airway inflammation and NF-kappaB signal activation. *Journal of cellular*
598 *biochemistry*. 2018;119 2:1746-54; doi: 10.1002/jcb.26335.
599 <http://www.ncbi.nlm.nih.gov/pubmed/28786504>.
- 600 28. Frontiñán-Rubio J, Gómez MV, Martín C, González-Domínguez JM, Durán-Prado M,
601 Vázquez E. Differential effects of graphene materials on the metabolism and function of
602 human skin cells. *Nanoscale*. 2018;10 24:11604-15; doi: 10.1039/c8nr00897c.
- 603 29. Pelin M, Fusco L, Leon V, Martin C, Criado A, Sosa S, et al. Differential cytotoxic effects
604 of graphene and graphene oxide on skin keratinocytes. *Scientific reports*. 2017;7:40572;
605 doi: 10.1038/srep40572. <http://www.ncbi.nlm.nih.gov/pubmed/28079192>.
- 606 30. Yu DS, Kuila T, Kim NH, Khanra P, Lee JH. Effects of covalent surface modifications on
607 the electrical and electrochemical properties of graphene using sodium 4-
608 aminoazobenzene-4'-sulfonate. *Carbon*. 2013;54:310-22; doi:
609 10.1016/j.carbon.2012.11.043.
- 610 31. Jiang T, Kuila T, Kim NH, Ku B-C, Lee JH. Enhanced mechanical properties of silanized
611 silica nanoparticle attached graphene oxide/epoxy composites. *Composites Science and*
612 *Technology*. 2013;79:115-25; doi: 10.1016/j.compscitech.2013.02.018.
- 613 32. Some S, Kim Y, Yoon Y, Yoo H, Lee S, Park Y, et al. High-Quality Reduced Graphene
614 Oxide by a Dual-Function Chemical Reduction and Healing Process. *Scientific reports*.
615 2013;3 1; doi: 10.1038/srep01929.
- 616 33. Torrisi F, Hasan T, Wu W, Sun Z, Lombardo A, Kulmala TS, et al. Inkjet-Printed Graphene
617 Electronics. *ACS nano*. 2012;6 4:2992-3006; doi: 10.1021/nn2044609.
- 618 34. Paton KR, Varrla E, Backes C, Smith RJ, Khan U, O'Neill A, et al. Scalable production of
619 large quantities of defect-free few-layer graphene by shear exfoliation in liquids. *Nature*
620 *Materials*. 2014;13 6:624-30; doi: 10.1038/nmat3944.
- 621 35. Watcharotone S, Dikin DA, Stankovich S, Piner R, Jung I, Dommert GHB, et al.
622 Graphene-Silica Composite Thin Films as Transparent Conductors. *Nano letters*. 2007;7
623 7:1888-92; doi: 10.1021/nl070477+.
- 624 36. Ou L, Lin S, Song B, Liu J, Lai R, Shao L. The mechanisms of graphene-based materials-
625 induced programmed cell death: a review of apoptosis, autophagy, and programmed
626 necrosis. *International journal of nanomedicine*. 2017;Volume 12:6633-46; doi:
627 10.2147/ijn.S140526.

- 628 37. Mohammadinejad R, Moosavi MA, Tavakol S, Vardar DO, Hosseini A, Rahmati M, et al.
629 Necrotic, apoptotic and autophagic cell fates triggered by nanoparticles. *Autophagy*.
630 2019;15 1:4-33; doi: 10.1080/15548627.2018.1509171.
631 <https://www.ncbi.nlm.nih.gov/pubmed/30160607>.
- 632 38. Martin SJ, Henry CM. Distinguishing between apoptosis, necrosis, necroptosis and other
633 cell death modalities. *Methods*. 2013;61 2:87-9; doi: 10.1016/j.ymeth.2013.06.001.
- 634 39. Tabish TA, Pranjol MZI, Hayat H, Rahat AAM, Abdullah TM, Whatmore JL, et al. In vitro
635 toxic effects of reduced graphene oxide nanosheets on lung cancer cells.
636 *Nanotechnology*. 2017;28 50:504001; doi: 10.1088/1361-6528/aa95a8.
637 <https://www.ncbi.nlm.nih.gov/pubmed/29064374>.
- 638 40. Nishida K, Yamaguchi O, Otsu K. Crosstalk between autophagy and apoptosis in heart
639 disease. *Circulation research*. 2008;103 4:343-51; doi:
640 10.1161/CIRCRESAHA.108.175448. <https://www.ncbi.nlm.nih.gov/pubmed/18703786>.
- 641 41. He T, Long J, Li J, Liu L, Cao Y. Toxicity of ZnO nanoparticles (NPs) to A549 cells and
642 A549 epithelium in vitro: Interactions with dipalmitoyl phosphatidylcholine (DPPC).
643 *Environmental toxicology and pharmacology*. 2017;56:233-40; doi:
644 10.1016/j.etap.2017.10.002. <https://www.ncbi.nlm.nih.gov/pubmed/29028602>.
- 645 42. Martin A, Sarkar A. Overview on biological implications of metal oxide nanoparticle
646 exposure to human alveolar A549 cell line. *Nanotoxicology*. 2017;11 6:713-24; doi:
647 10.1080/17435390.2017.1366574. <https://www.ncbi.nlm.nih.gov/pubmed/28830283>.
- 648 43. Yang Y, Han P, Xie X, Yin X, Duan G, Wen L. Protein corona reduced graphene oxide
649 cytotoxicity by inhibiting endocytosis. *Colloid and Interface Science Communications*.
650 2021;45; doi: 10.1016/j.colcom.2021.100514.
- 651 44. Cummings BS, Schnellmann RG. Measurement of Cell Death in Mammalian Cells.
652 *Current Protocols in Pharmacology*. 2004;25 1; doi: 10.1002/0471141755.ph1208s25.
- 653 45. Vanden Berghe T, Grootjans S, Goossens V, Dondelinger Y, Krysko DV, Takahashi N,
654 et al. Determination of apoptotic and necrotic cell death in vitro and in vivo. *Methods*.
655 2013;61 2:117-29; doi: 10.1016/j.ymeth.2013.02.011.
- 656 46. Jarosz A, Skoda M, Dudek I, Szukiewicz D. Oxidative Stress and Mitochondrial Activation
657 as the Main Mechanisms Underlying Graphene Toxicity against Human Cancer Cells.
658 *Oxidative medicine and cellular longevity*. 2016;2016:5851035; doi:
659 10.1155/2016/5851035. <https://www.ncbi.nlm.nih.gov/pubmed/26649139>.
- 660 47. Davis AS, Chertow DS, Moyer JE, Suzich J, Sandouk A, Dorward DW, et al. Validation
661 of normal human bronchial epithelial cells as a model for influenza A infections in human
662 distal trachea. *The journal of histochemistry and cytochemistry : official journal of the*
663 *Histochemistry Society*. 2015;63 5:312-28; doi: 10.1369/0022155415570968.
664 <https://www.ncbi.nlm.nih.gov/pubmed/25604814>.
- 665 48. Prytherch ZC, BeruBe KA. A normal and biotransforming model of the human bronchial
666 epithelium for the toxicity testing of aerosols and solubilised substances. *Alternatives to*
667 *laboratory animals : ATLA*. 2014;42 6:377-81; doi: 10.1177/026119291404200607.
668 <https://www.ncbi.nlm.nih.gov/pubmed/25635646>.
- 669 49. Rayner RE, Makena P, Prasad GL, Cormet-Boyaka E. Optimization of Normal Human
670 Bronchial Epithelial (NHBE) Cell 3D Cultures for in vitro Lung Model Studies. *Scientific*
671 *reports*. 2019;9 1:500; doi: 10.1038/s41598-018-36735-z.
672 <https://www.ncbi.nlm.nih.gov/pubmed/30679531>.
- 673 50. Mudusu D, Nandanapalli KR, Lee S, Hahn YB. Recent advances in graphene monolayers
674 growth and their biological applications: A review. *Advances in colloid and interface*
675 *science*. 2020;283:102225; doi: 10.1016/j.cis.2020.102225.
676 <https://www.ncbi.nlm.nih.gov/pubmed/32777519>.
- 677 51. Song S, Shen H, Wang Y, Chu X, Xie J, Zhou N, et al. Biomedical application of graphene:
678 From drug delivery, tumor therapy, to theranostics. *Colloids and surfaces B,*
679 *Biointerfaces*. 2020;185:110596; doi: 10.1016/j.colsurfb.2019.110596.
680 <https://www.ncbi.nlm.nih.gov/pubmed/31707226>.
- 681 52. Ramaiah GB, Tegegne A, Melese B. Functionality of nanomaterials and its technological
682 aspects – Used in preventing, diagnosing and treating COVID-19. *Materials Today:*
683 *Proceedings*. 2021; doi: 10.1016/j.matpr.2021.04.306.
- 684 53. Tran TS, Dutta NK, Choudhury NR. Graphene inks for printed flexible electronics:
685 Graphene dispersions, ink formulations, printing techniques and applications. *Advances*
686 *in colloid and interface science*. 2018;261:41-61; doi: 10.1016/j.cis.2018.09.003.

- 687 54. Szunerits S, Boukherroub R. Graphene-based biosensors. *Interface Focus*. 2018;8
688 3:20160132; doi: 10.1098/rsfs.2016.0132.
689 <https://www.ncbi.nlm.nih.gov/pubmed/29696084>.
- 690 55. Gao X, Lowry GV. Progress towards standardized and validated characterizations for
691 measuring physicochemical properties of manufactured nanomaterials relevant to nano
692 health and safety risks. *NanoImpact*. 2018;9:14-30; doi: 10.1016/j.impact.2017.09.002.
- 693 56. Bellagamba I, Boccuni F, Ferrante R, Tombolini F, Marra F, Sarto MS, et al. Workers'
694 Exposure Assessment during the Production of Graphene Nanoplatelets in R&D
695 Laboratory. *Nanomaterials*. 2020;10 8; doi: 10.3390/nano10081520.
- 696 57. Dong C, Wang Y, Gonzalez GX, Ma Y, Song Y, Wang S, et al. Intranasal vaccination with
697 influenza HA/GO-PEI nanoparticles provides immune protection against homo- and
698 heterologous strains. *Proceedings of the National Academy of Sciences*. 2021;118 19;
699 doi: 10.1073/pnas.2024998118.
- 700 58. Qu G, Wang X, Liu Q, Liu R, Yin N, Ma J, et al. The ex vivo and in vivo biological
701 performances of graphene oxide and the impact of surfactant on graphene oxide's
702 biocompatibility. *Journal of Environmental Sciences*. 2013;25 5:873-81; doi:
703 10.1016/s1001-0742(12)60252-6.
- 704 59. Sasidharan A, Swaroop S, Koduri CK, Girish CM, Chandran P, Panchakarla LS, et al.
705 Comparative in vivo toxicity, organ biodistribution and immune response of pristine,
706 carboxylated and PEGylated few-layer graphene sheets in Swiss albino mice: A three
707 month study. *Carbon*. 2015;95:511-24; doi: 10.1016/j.carbon.2015.08.074.
- 708 60. Zhang D, Zhang Z, Liu Y, Chu M, Yang C, Li W, et al. The short- and long-term effects of
709 orally administered high-dose reduced graphene oxide nanosheets on mouse behaviors.
710 *Biomaterials*. 2015;68:100-13; doi: 10.1016/j.biomaterials.2015.07.060.
- 711 61. El-Yamany NA, Mohamed FF, Salaheldin TA, Tohamy AA, Abd El-Mohsen WN, Amin
712 AS. Graphene oxide nanosheets induced genotoxicity and pulmonary injury in mice.
713 *Experimental and toxicologic pathology : official journal of the Gesellschaft fur*
714 *Toxikologische Pathologie*. 2017;69 6:383-92; doi: 10.1016/j.etp.2017.03.002.
715 <http://www.ncbi.nlm.nih.gov/pubmed/28359838>.
- 716 62. Amrollahi-Sharifabadi M, Koochi MK, Zayerzadeh E, Hablolvarid MH, Hassan J, Seifalian
717 AM. In vivo toxicological evaluation of graphene oxide nanoplatelets for clinical
718 application. *International journal of nanomedicine*. 2018;Volume 13:4757-69; doi:
719 10.2147/ijn.S168731.
- 720 63. Schinwald A, Murphy F, Askounis A, Koutsos V, Sefiane K, Donaldson K, et al. Minimal
721 oxidation and inflammogenicity of pristine graphene with residence in the lung.
722 *Nanotoxicology*. 2014;8 8:824-32; doi: 10.3109/17435390.2013.831502.
723 <https://www.ncbi.nlm.nih.gov/pubmed/23924429>.
- 724 64. Kim YH, Jo MS, Kim JK, Shin JH, Baek JE, Park HS, et al. Short-term inhalation study of
725 graphene oxide nanoplates. *Nanotoxicology*. 2018;12 3:224-38; doi:
726 10.1080/17435390.2018.1431318. <https://www.ncbi.nlm.nih.gov/pubmed/29385887>.
- 727 65. Mittal S, Kumar V, Dhiman N, Chauhan LK, Pasricha R, Pandey AK. Physico-chemical
728 properties based differential toxicity of graphene oxide/reduced graphene oxide in human
729 lung cells mediated through oxidative stress. *Scientific reports*. 2016;6:39548; doi:
730 10.1038/srep39548. <https://www.ncbi.nlm.nih.gov/pubmed/28000740>.
- 731 66. Roberts JR, Mercer RR, Stefaniak AB, Seehra MS, Geddam UK, Chaudhuri IS, et al.
732 Evaluation of pulmonary and systemic toxicity following lung exposure to graphite
733 nanoplates: a member of the graphene-based nanomaterial family. *Particle and fibre*
734 *toxicology*. 2016;13 1; doi: 10.1186/s12989-016-0145-5.
- 735 67. Poulsen SS, Bengtson S, Williams A, Jacobsen NR, Troelsen JT, Halappanavar S, et al.
736 A transcriptomic overview of lung and liver changes one day after pulmonary exposure
737 to graphene and graphene oxide. *Toxicology and applied pharmacology*. 2021;410; doi:
738 10.1016/j.taap.2020.115343.
- 739 68. Ryffel B, Bengtson S, Knudsen KB, Kyjovska ZO, Berthing T, Skaug V, et al. Differences
740 in inflammation and acute phase response but similar genotoxicity in mice following
741 pulmonary exposure to graphene oxide and reduced graphene oxide. *PLoS one*. 2017;12
742 6; doi: 10.1371/journal.pone.0178355.
- 743 69. Rodrigues AF, Newman L, Jasim D, Mukherjee SP, Wang J, Vacchi IA, et al. Size-
744 Dependent Pulmonary Impact of Thin Graphene Oxide Sheets in Mice: Toward Safe-by-
745 Design. *Advanced Science*. 2020;7 12; doi: 10.1002/advs.201903200.
746 <https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/advs.201903200?download=true>.

- 747 70. Hussain SM, Warheit DB, Ng SP, Comfort KK, Grabinski CM, Braydich-Stolle LK. At the
748 Crossroads of Nanotoxicology in vitro: Past Achievements and Current Challenges.
749 Toxicological sciences : an official journal of the Society of Toxicology. 2015;147 1:5-16;
750 doi: 10.1093/toxsci/kfv106. <https://www.ncbi.nlm.nih.gov/pubmed/26310852>.
- 751 71. Pastor DM, Poritz LS, Olson TL, Kline CL, Harris LR, Koltun WA, et al. Primary cell lines:
752 false representation or model system? a comparison of four human colorectal tumors and
753 their coordinately established cell lines. Int J Clin Exp Med. 2010;3 1:69-83.
754 <https://www.ncbi.nlm.nih.gov/pubmed/20369042>.
- 755 72. Platel A, Privat K, Talahari S, Delobel A, Dourdin G, Gateau E, et al. Study of in vitro and
756 in vivo genotoxic effects of air pollution fine (PM_{2.5-0.18}) and quasi-ultrafine (PM_{0.18})
757 particles on lung models. The Science of the total environment. 2020;711:134666; doi:
758 10.1016/j.scitotenv.2019.134666. <https://www.ncbi.nlm.nih.gov/pubmed/31812380>.
- 759 73. Nurunnabi M, Khatun Z, Huh KM, Park SY, Lee DY, Cho KJ, et al. In Vivo Biodistribution
760 and Toxicology of Carboxylated Graphene Quantum Dots. ACS nano. 2013;7 8:6858-67;
761 doi: 10.1021/nn402043c.
- 762 74. Mittal S, Sharma PK, Tiwari R, Rayavarapu RG, Shankar J, Chauhan LKS, et al. Impaired
763 lysosomal activity mediated autophagic flux disruption by graphite carbon nanofibers
764 induce apoptosis in human lung epithelial cells through oxidative stress and energetic
765 impairment. Particle and fibre toxicology. 2017;14 1; doi: 10.1186/s12989-017-0194-4.
- 766 75. Chng ELK, Pumera M. The Toxicity of Graphene Oxides: Dependence on the Oxidative
767 Methods Used. Chemistry - A European Journal. 2013;19 25:8227-35; doi:
768 10.1002/chem.201300824.
- 769 76. Barahuie F, Saifullah B, Dorniani D, Fakurazi S, Karthivashan G, Hussein MZ, et al.
770 Graphene oxide as a nanocarrier for controlled release and targeted delivery of an
771 anticancer active agent, chlorogenic acid. Materials Science and Engineering: C.
772 2017;74:177-85; doi: 10.1016/j.msec.2016.11.114.
- 773 77. Gupta N, Jangid AK, Singh M, Pooja D, Kulhari H. Designing Two-Dimensional
774 Nanosheets for Improving Drug Delivery to Fucose-Receptor-Overexpressing Cancer
775 Cells. ChemMedChem. 2018;13 24:2644-52; doi: 10.1002/cmdc.201800575.
- 776 78. Silva MM, Rocha CRR, Kinker GS, Pelegrini AL, Menck CFM. The balance between
777 NRF2/GSH antioxidant mediated pathway and DNA repair modulates cisplatin resistance
778 in lung cancer cells. Scientific reports. 2019;9 1:17639; doi: 10.1038/s41598-019-54065-
779 6. <https://www.ncbi.nlm.nih.gov/pubmed/31776385>.
- 780 79. Losacco C, Perillo A. Particulate matter air pollution and respiratory impact on humans
781 and animals. Environmental Science and Pollution Research. 2018;25 34:33901-10; doi:
782 10.1007/s11356-018-3344-9.
- 783 80. Fiorito S, Mastrofrancesco A, Cardinali G, Rosato E, Salsano F, Su DS, et al. Effects of
784 carbonaceous nanoparticles from low-emission and older diesel engines on human skin
785 cells. Carbon. 2011;49 15:5038-48; doi: 10.1016/j.carbon.2011.07.022.
- 786 81. Matsuo M, Shimada T, Uenishi R, Sasaki N, Sagai M. Diesel exhaust particle-induced
787 cell death of cultured normal human bronchial epithelial cells. Biological & pharmaceutical
788 bulletin. 2003;26 4:438-47; doi: 10.1248/bpb.26.438.
789 <https://www.ncbi.nlm.nih.gov/pubmed/12673022>.
- 790 82. Vattanasit U, Navasumrit P, Khadka MB, Kanitwithayanun J, Promvijit J, Autrup H, et al.
791 Oxidative DNA damage and inflammatory responses in cultured human cells and in
792 humans exposed to traffic-related particles. Int J Hyg Environ Health. 2014;217 1:23-33;
793 doi: 10.1016/j.ijheh.2013.03.002. <https://www.ncbi.nlm.nih.gov/pubmed/23567252>.
- 794 83. González-Domínguez JM, León V, Lucío MI, Prato M, Vázquez E. Production of ready-
795 to-use few-layer graphene in aqueous suspensions. Nature protocols. 2018;13 3:495-
796 506; doi: 10.1038/nprot.2017.142.
- 797 84. González VJ, Rodríguez AM, León V, Frontiñán-Rubio J, Fierro JLG, Durán-Prado M, et
798 al. Sweet graphene: exfoliation of graphite and preparation of glucose-graphene
799 cocrystals through mechanochemical treatments. Green Chemistry. 2018;20 15:3581-92;
800 doi: 10.1039/c8gc01162a.
- 801 85. León V, González-Domínguez JM, Fierro JLG, Prato M, Vázquez E. Production and
802 stability of mechanochemically exfoliated graphene in water and culture media.
803 Nanoscale. 2016;8 30:14548-55; doi: 10.1039/c6nr03246j.
- 804 86. Duran-Prado M, Frontinan J, Santiago-Mora R, Peinado JR, Parrado-Fernandez C,
805 Gomez-Almagro MV, et al. Coenzyme Q10 protects human endothelial cells from beta-

806 amyloid uptake and oxidative stress-induced injury. PloS one. 2014;9 10:e109223; doi:
807 10.1371/journal.pone.0109223. <http://www.ncbi.nlm.nih.gov/pubmed/25272163>.
808 87. Frontiñan-Rubio J, Gomez MV, González VJ, Durán-Prado M, Vázquez E. Sublethal
809 exposure of small few-layer graphene promotes metabolic alterations in human skin cells.
810 Scientific reports. 2020;10 1; doi: 10.1038/s41598-020-75448-0.

811

812 **Figure legends**

813 **Figure 1.** Characterization of GO, FLG, and sFLG: (A) HRTEM Image (GO scale bar:
814 200nm; FLG scale bar: 100 nm; sFLG scale bar: 20 nm); (B) lateral size distribution of
815 flakes; (C) lateral size distribution of sFLG; (D) TGA results in nitrogen atmosphere; (E)
816 Raman spectra; and (F) elemental analysis of nanomaterials.






817 **Figure 2.** Effect of GO, FLG, and sFLG on NHBE cell necrosis: percentage of necrosis
818 in NHBE cells treated with increasing concentrations of GO, FLG, or sFLG for 6 hours
819 (A), 24 hours (B), and 7 days (C). Data are shown as percentage \pm SEM (* p <0.05;
820 ** p <0.01, *** p <0.001; **** p <0.0001; n =4).

821 **Figure 3.** Effect of GO, FLG, and sFLG on A549 cell necrosis and apoptosis: percentage
822 of necrotic (A) or apoptotic cells (B) in cells treated with GO, FLG, or sFLG for 24 hours.
823 Gray bars represent the levels of necrosis or apoptosis in NHBE. Data are shown as
824 percentage \pm SEM (* p <0.05; ** p <0.01; n =3).

825 **Figure 4.** Effect of GO, FLG, and sFLG on cell viability. Percentage of viable NHBE and
826 A549 cells treated with GO, FLG, or sFLG for 24 hours (A) and 7 days (B). Data are
827 shown as percentage \pm SEM (* p <0.05; ** p <0.01, *** p <0.001; **** p <0.0001; n =3).

828 **Figure 5.** Effect of GO, FLG, and sFLG on Ca^{2+} homeostasis and ROS levels in NHBE
829 and A549 cells: cytosolic (A), mitochondrial (B) Ca^{2+} ratio, H_2O_2 (C) and O_2^- (D) in NHBE
830 or A549 cells treated with 5 $\mu\text{g}/\text{mL}$ GO, FLG, or sFLG for 24 hours. Data are shown as
831 mean \pm SEM (* p <0.05; ** p <0.01, *** p <0.001; n =3).

832 **Figure 6.** Effects of different compounds on NHBE cell death. The graph displays the
833 cell death values of: cigarette mainstream smoke (CMS) [23], E-liquid [23], GO with
834 chitosan (CHI) and hyaluronic acid (HA) [24], cigarette smoke extract [25], diesel exhaust
835 particles (DEPs) [26], *Aspergillus fumigatus* [27], and particle matter (PM) (2.50–0.18
836 nm) [72]. Blue, red, or green lines represent the toxicity induced by GO, FLG, and sFLG.



F

Sample	%C	%H	%N	%S	%O
GO	47.04 ±0.11	3.05 ±0.03	0.15 ±0.01	1.38 ±0.01	48.38 ±0.04
FLG	91.62 ±0.43	0.79 ±0.02	0.55 ±0.02	0.51 ±0.02	6.53 ±0.12
sFLG	90.16 ±0.21	0.69 ±0.02	0.08 ±0.02	0.07 ±0.01	9.19 ±0.43

